Indivior Pharmaceuticals (INDV) Gross Margin (2024 - 2026)

Indivior Pharmaceuticals' Gross Margin history runs 3 years deep, the most recent figure standing at 87.38% for Q1 2026.

• In Q1 2026, Gross Margin rose 430.0% year-over-year to 87.38%; the TTM figure through Mar 2026 stood at 81.25% (up 166.0% YoY), while the FY2025 annual figure was 80.23%, down 33.0% from the prior year.
• Gross Margin was 87.38% for Q1 2026 at Indivior Pharmaceuticals, up from 81.56% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 87.38% in Q1 2026 to a low of 73.25% in Q3 2025.
• Historically, Gross Margin has averaged 81.15% across 3 years, with a median of 82.78% in 2025.
• Biggest YoY gain for Gross Margin was 920 bps in 2025; the steepest drop was 525 bps in 2025.
• A 3-year view of Gross Margin shows it stood at 83.61% in 2024, then slipped by 2 bps to 81.56% in 2025, then increased by 7 bps to 87.38% in 2026.
• The last three Gross Margin figures came in at 87.38% (Q1 2026), 81.56% (Q4 2025), and 73.25% (Q3 2025), per Business Quant data.